Compare
AbbVie vs Biogen (ABBV vs BIIB)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Biogen (BIIB) +61.9%; so far this year the figures are +27.5% and +41.1%.
AbbVie is the larger company by market value, about 14.0 times the size of Biogen.
On trailing earnings, ABBV trades at 50.1 times and BIIB at 107.0 times.
Revenue grew +10.7% at ABBV and +2.3% at BIIB over the last year.
ABBV yields 2.38%. BIIB pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | BIIB | |
|---|---|---|
| Price | $291.31 | $248.35 |
| 1-day | +1.07% | +1.81% |
| YTD | +27.49% | +41.12% |
| 1 year | +34.39% | +61.87% |
| 3 years | +104.47% | +3.64% |
| Market cap | $514.9B | $36.7B |
| P/E | 50.1 | 107.0 |
| P/S | 7.80 | 3.57 |
| P/B | — | 1.94 |
| Revenue growth | +10.70% | +2.30% |
| EPS growth | +340.20% | -78.90% |
| Gross margin % | 73.7 | 74.0 |
| Net margin % | 15.7 | 3.4 |
| ROE % | — | 1.8 |
| Debt / equity | — | 0.39 |
| FCF yield % | 3.7 | 5.6 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.33 |
| RSI (14) | 59.7 | 57.0 |
| Technical rating |